| scholarly article | Q13442814 |
| P50 | author | Jeremiah J Trudeau | Q60312382 |
| Dennis A Revicki | Q91415021 | ||
| Sandra D Comer | Q109482605 | ||
| P2093 | author name string | Nathaniel P Katz | |
| Joseph W Stauffer | |||
| Richard G van Inwegen | |||
| Thomas A Eaton | |||
| P2860 | cites work | Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. | Q50925495 |
| Research design strategies to evaluate the impact of formulations on abuse liability | Q59488289 | ||
| Estimating clinically significant differences in quality of life outcomes | Q81745377 | ||
| Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance | Q29615569 | ||
| Depot naltrexone: long-lasting antagonism of the effects of heroin in humans | Q33837599 | ||
| Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation | Q34193483 | ||
| Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial | Q34357213 | ||
| Methods to explain the clinical significance of health status measures | Q34590636 | ||
| Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes | Q34733490 | ||
| Defining the clinically important difference in pain outcome measures | Q39425027 | ||
| Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire | Q39602227 | ||
| Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo- | Q43248767 | ||
| Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life | Q43789921 | ||
| Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study | Q44336112 | ||
| P433 | issue | 6 | |
| P921 | main subject | opioid | Q427523 |
| P304 | page(s) | 975-981 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Quality of Life Research | Q15749950 |
| P1476 | title | Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations | |
| P478 | volume | 21 |
| Q51730973 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. |
| Q37265572 | Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users |
| Q44339796 | Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recr |
| Q33769077 | At-risk and intervention thresholds of occupational stress using a visual analogue scale |
| Q30240248 | Current and future development of extended-release, abuse-deterrent opioid formulations in the United States |
| Q44340245 | Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users |
| Q39574546 | Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales |
| Q37717944 | Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER). |
Search more.